West Pharmaceutical Services, Inc. (WST) Earnings History
Annual and quarterly earnings data from 1989 to 2025
Loading earnings history...
WST EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
WST Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 35.9% | 20.1% | 16.1% |
| 2024 | 34.6% | 20.6% | 17.0% |
| 2023 | 38.4% | 24.1% | 20.1% |
| 2022 | 39.5% | 26.5% | 20.3% |
| 2021 | 41.5% | 26.8% | 23.4% |
Download Data
Export WST earnings history in CSV or JSON format
Free sign-in required to download data
West Pharmaceutical Services, Inc. (WST) Earnings Overview
As of May 8, 2026, West Pharmaceutical Services, Inc. (WST) reported trailing twelve-month net income of $543M, reflecting +1.6% year-over-year growth. The company earned $7.50 per diluted share over the past four quarters, with a net profit margin of 16.1%.
Looking at the long-term picture, WST's 5-year EPS compound annual growth rate (CAGR) stands at +8.3%, showing solid earnings momentum. The company achieved its highest annual net income of $662M in fiscal 2021.
West Pharmaceutical Services, Inc. maintains industry-leading profitability with a gross margin of 35.9%, operating margin of 20.1%, and net margin of 16.1%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including ATR ($387M net income, 10.4% margin), GTLS ($40M net income, 1.0% margin), AVTR (-$551M net income, -8.1% margin), WST has outperformed on profitability metrics. Compare WST vs ATR →
WST Earnings vs Peers
Earnings metrics vs comparable public companies
WST Historical Earnings Data (1989–2025)
37 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $494M | +0.2% | $617M | $6.80 | 16.1% | 20.1% |
| 2024 | $493M | -17.0% | $595M | $6.69 | 17.0% | 20.6% |
| 2023 | $593M | +1.3% | $711M | $7.88 | 20.1% | 24.1% |
| 2022 | $586M | -11.5% | $764M | $7.73 | 20.3% | 26.5% |
| 2021 | $662M | +91.2% | $759M | $8.67 | 23.4% | 26.8% |
| 2020 | $346M | +43.2% | $419M | $4.57 | 16.1% | 19.5% |
| 2019 | $242M | +16.8% | $297M | $3.21 | 13.1% | 16.1% |
| 2018 | $207M | +37.3% | $255M | $2.74 | 12.0% | 14.8% |
| 2017 | $151M | +4.9% | $230M | $1.99 | 9.4% | 14.4% |
| 2016 | $144M | +50.2% | $216M | $1.91 | 9.5% | 14.3% |
Full WST Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See WST's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs WST Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare WST vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonWST — Frequently Asked Questions
Quick answers to the most common questions about buying WST stock.
Is WST growing earnings?
WST EPS of $7.50 reflects slowing growth at +1.6%, below the 5-year CAGR of +8.3%. TTM net income is $543M. Expansion rate has moderated.
What are WST's profit margins?
West Pharmaceutical Services, Inc. net margin is +16.1%, with operating margin at +20.1%. Above-average margins indicate pricing power.
How consistent are WST's earnings?
WST earnings data spans 1989-2025. The current earnings trend is +1.6% YoY. Historical data enables comparison across business cycles.